Levofloxacin for the treatment of severe refractory BK virus‑associated hemorrhagic cystitis in hematopoietic stem cell transplantation recipients: A report of three cases
- Authors:
- Tayfur Toptas
- Isik Kaygusuz‑Atagunduz
- Haluk Tarik Kani
- Cafer Adiguzel
- Tulin Firatli‑Tuglular
View Affiliations
Affiliations: Department of Hematology, Van Training and Research Hospital, Van 65100, Turkey, Department of Hematology, Marmara University Hospital, Istanbul 34890, Turkey
- Published online on: July 25, 2014 https://doi.org/10.3892/ol.2014.2381
-
Pages:
1775-1777
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
BK‑virus (BKV) is an important etiological agent for late‑onset hemorrhagic cystitis (HC) in patients undergoing hematopoietic stem cell transplantation. Late‑onset HC causes significant morbidity among these patients. Therapeutic approaches remain predominantly symptomatic. Several treatment options have been used with variable success rates. Cidofovir has the highest specificity against BKV; however, its lack of availability in the majority of countries, high costs and potential nephrotoxic effects limit its use. The present study reports three cases of severe and prolonged BKV‑associated HC (BKHC). HC was resolved in all three of the patients using oral levofloxacin. Thus, levofloxacin may be an effective treatment modality for achieving complete clinical and molecular response in patients with refractory, severe BKHC.
View References
|
1
|
Gratwohl A, Brand R, Frassoni F, et al:
Cause of death after allogeneic haematopoietic stem cell
transplantation (HSCT) in early leukaemias: an EBMT analysis of
lethal infectious complications and changes over calendar time.
Bone Marrow Transplant. 36:757–769. 2005.
|
|
2
|
Harkensee C, Vasdev N, Gennery AR,
Willetts IE and Taylor C: Prevention and management of BK-virus
associated haemorrhagic cystitis in children following
haematopoietic stem cell transplantation - a systematic review and
evidence-based guidance for clinical management. Br J Haematol.
142:717–731. 2008.
|
|
3
|
Gardner SD, Field AM, Coleman DV, et al:
New human papovavirus (B.K.) isolated from urine after renal
transplantation. Lancet. 1:1253–1257. 1971.
|
|
4
|
Leung AY, Suen CK, Lie AK, Liang RH, Yuen
KY and Kwong YL: Quantification of polyoma BK viruria in
hemorrhagic cystitis complicating bone marrow transplantation.
Blood. 98:1971–1978. 2001.
|
|
5
|
Leung AY, Mak R, Lie AK, et al:
Clinicopathological features and risk factors of clinically overt
haemorrhagic cystitis complicating bone marrow transplantation.
Bone Marrow Transplant. 29:509–513. 2002.
|
|
6
|
Focosi D and Kast RE: Hyaluronate and
risperidone for hemorrhagic cystitis. Bone Marrow Transplant.
39:572007.
|
|
7
|
Leung AY, Chan MT, Yuen KY, et al:
Ciprofloxacin decreased polyoma BK virus load in patients who
underwent allogeneic hematopoietic stem cell transplantation. Clin
Infect Dis. 40:528–537. 2005.
|
|
8
|
Kwon HJ, Kang JH, Lee JW, Chung NG, Kim HK
and Cho B: Treatment of BK virus-associated hemorrhagic cystitis in
pediatric hematopoietic stem cell transplant recipients with
cidofovir: a single-center experience. Transpl Infect Dis.
15:569–574. 2013.
|
|
9
|
Gabardi S, Waikar SS, Martin S, et al:
Evaluation of fluoroquinolones for the prevention of BK viremia
after renal transplantation. Clin J Am Soc Nephrol. 5:1298–1304.
2010.
|
|
10
|
Lee BT, Gabardi S, Grafals M, et al:
Efficacy of levofloxacin in the treatment of BK viremia: a
multicenter, double-blinded, randomized, placebo-controlled trial.
Clin J Am Soc Nephrol. 9:583–589. 2014.
|
